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Abstract
Emerging evidence has highlighted the pivotal role of microvasculature injury in the devel-
opment and progression of renal fibrosis. Angiopoietin-1 (Ang-1) is a secreted vascular
growth factor that binds to the endothelial-specific Tie2 receptor. Ang-1/Tie2 signaling is
critical for regulating blood vessel development and modulating vascular response after
injury, but is dispensable in mature, quiescent vessels. Although dysregulation of vascular
endothelial growth factor (VEGF) signaling has been well studied in renal pathologies,
much less is known about the role of the Ang-1/Tie2 pathway in renal interstitial fibrosis.
Previous studies have shown contradicting effects of overexpressing Ang-1 systemically on
renal tubulointerstitial fibrosis when different engineered forms of Ang-1 are used. Here, we
investigated the impact of site-directed expression of native Ang-1 on the renal fibrogenic
process and peritubular capillary network by exploiting a conditional transgenic mouse sys-
tem [Pax8-rtTA/(TetO)7 Ang-1] that allows increased tubular Ang-1 production in adult mice.
Using a murine unilateral ureteral obstruction (UUO) fibrosis model, we demonstrate that
targeted Ang-1 overexpression attenuates myofibroblast activation and interstitial collagen I
accumulation, inhibits the upregulation of transforming growth factor β1 and subsequent
phosphorylation of Smad 2/3, dampens renal inflammation, and stimulates the growth of
peritubular capillaries in the obstructed kidney. Our results suggest that Ang-1 is a potential
therapeutic agent for targeting microvasculature injury in renal fibrosis without compromis-
ing the physiologically normal vasculature in humans.
Introduction
Renal fibrosis, characterized by interstitial myofibroblast activation and excessive matrix pro-
tein accumulation, is the final common pathway of chronic kidney disease (CKD) [1, 2].
Mounting evidence has demonstrated the pivotal role of the renal microvasculature in the
development of interstitial fibrosis and CKD progression. Injury to the renal peritubular capil-
lary network leads to capillary rarefaction, tubulointerstitial hypoxia, recruitment of
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inflammatory cells, and renal fibrosis [3–5]. Conversely, growth factors or cytokines with
endothelial cell (EC) protective effects have been shown to ameliorate renal fibrosis in experi-
mental models of renal fibrosis [6, 7]. Therefore, targeting the renal vasculature may be a
promising therapeutic strategy to attenuate renal fibrosis.
Angiopoietins (Angs) are a family of vascular growth factors that bind to the EC specific tyro-
sine kinase receptor Tie2. Ang-1 and Ang-3 are agonists while Ang-2 and Ang-4 are antagonists
for Tie2 [8–10]. Ang-1 is a 55-kDa glycoprotein secreted by proximal tubular cells and podocytes
in the kidney [11], and it has a number of important functions in ECs as follows. 1. Ang-1 acts as a
stabilization factor for new endothelial network formation through Ang-1-Tie2 paracrine signaling
[12]. 2. Ang-1 is a strong anti-apoptotic survival factor in ECs [13]. 3. Ang-1 induces EC sprouting
in vitro [14]. 4. Ang-1 stimulates ECmigration in vitro [15]. In addition, Ang-1 has potent anti-
inflammatory and anti-permeability effects [16, 17] and antagonizes the pro-angiogenic and pro-
inflammatory actions of Ang-2 and vascular endothelial growth factor (VEGF) [18]. In summary,
Ang-1 is a major physiological ligand for Tie2 and plays important roles in prenatal and postnatal
vascular development. However, it is dispensable in mature and quiescent vessels [19].
Dysregulation of the Ang-1/Tie2 system has been shown to be an important feature of CKD
in human patients [20]. Previous studies examining the therapeutic role of Ang-1 in renal
tubulointerstitial disease have provided conflicting results. Kim et al. [21] showed that viral
delivery of a chimeric form of Ang-1, cartilage oligomeric matrix protein-Ang-1 (COMP-Ang-
1; a soluble and more potent Ang-1 variant than native Ang-1) preserves peritubular capillaries
and decreases renal fibrosis and inflammation in a murine unilateral ureteral obstruction
(UUO) fibrosis model. In contrast, Long et al. [22] found that administration of Ang-1, a
more soluble form of Ang-1, stabilizes peritubular capillaries in the chronic phase of folic acid
(FA)-induced nephrotoxicity in mice, which is characterized by capillary loss and interstitial
fibrosis. However, at the same time, the use of Ang-1 was accompanied by pro-fibrotic and
pro-inflammatory effects. To determine the therapeutic potential of native Ang-1 in renal
fibrosis, we have utilized a tetracycline-based binary conditional transgenic approach to over-
express Ang-1 specifically in mature renal tubules. We demonstrate here that enhanced tubular
Ang-1 expression halts the progression of renal fibrosis in association with decreased renal
inflammation and increased peritubular capillaries in a murine UUOmodel.
Materials and Methods
Generation of DOX-inducible TETAng-1 transgenic mice
All animal experiments conformed to the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Washington University Animal Studies
Committee.
The (TetO)7/CMV-Ang-1-ZsGreen transgene contains the (TetO)7/CMV regulatory ele-
ment (a gift from Jeffrey Miner, Washington University in St. Louis) driving a mouse Ang-1
cDNA, followed by an internal ribosome entry site (IRES), the ZsGreen cDNA and an SV40
polyadenylylation signal. Mouse Ang-1 was obtained from the plasmid pSPORT1-Ang-1
(ATCC, Manassas, VA) and cloned into the plasmid pIRES2-ZsGreen1 (Clontech, Mountain
View, CA). The insert Ang-1-IRES-ZsGreen was subsequently cloned into the (TetO)7/CMV
plasmid. TetAng-1 transgenic mice were identified by PCR using a primer pair (5’-TGCCACG
TTGTGAGTTGGATAGTT-3’ and 5’-ACATGCAGTTCTCCTCCACGCT-3’) that amplifies a
593-bp fragment of the transgenic cDNA. The Pax8-rtTA (P8TA) transgenic mice were pur-
chased from The Jackson Laboratory (JAX stock # 7176). P8TA mice were identified by PCR
using a primer pair (5’-CCATGTCTAGACTGGACAAGA-3’ and 5’-CTCCAGGCCACATAT
GATTAG-3’) to generate an approximately 600-bp amplicon.
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Transgenes were purified away from plasmid vector sequences and microinjected into the
pronucleus of B6CBAF2/J single-celled embryos. To induce transgene expression, mice were
fed TestDiet Modified LabDiet Rodent Diet 5001 containing 1500 ppm doxycycline (purchased
from El-Mel, Inc, Florissant, MO) at three weeks of age for 8 weeks. Experimental mice
remained on doxycycline food continuously, as did their single-transgene control littermates
that were analyzed for comparison. At the end of experiments, mice were euthanized using
intraperitoneal injection of ketamine/xylazine, followed by cervical dislocation. All procedures
followed the American Veterinary Medical Association (AVMA) guide.
Unilateral ureteral obstruction
A unilateral ureteral obstruction was created in 11-week-old bitransgenic P8TA/Ang-1 or sin-
gle-transgene (Ang-1/+ or P8TA/+) control mice by surgically placing a microvascular clamp
on the proximal ureter [23]. All procedures were approved by institutional review.
Sirius Red staining
Paraffin sections of mouse kidneys were examined for renal fibrosis with the Picro-Sirius Red
staining. Briefly, deparaffinized sections were treated with 0.1% Sirius Red in saturated picric
acid (Sigma, St Louis, MO) and destained in 0.5% acetic acid. Collagen fibrils were stained and
evaluated under light microscopy (Nikon) equipped with a polarizer. Ten randomly selected
fields (magnification, x400) from cortex and medullar, respectively, in each kidney were evalu-
ated and all images were captured by Olympus DP72 Capture Interface software. Ratio of Sirius
red positive areas to whole areas in each field was calculated in percentages by Image J (NIH)
software.
Antibodies and reagents
Commercially available antibodies were obtained as follows: rabbit anti-mouse α-smooth
muscle actin (α-SMA), rabbit anti-mouse collagen I, rat anti-mouse F4/80 (CI:A3-1), rabbit-
anti-mouse CD31 antibodies were from Abcam (Cambridge, England), rabbit anti-mouse
phospho-Smad 2/3(D27F4) and Smad2/3 (D7G7), rabbit anti-mouse GAPDH (D16H11)
antibodies were from Cell Signaling (Danvers, Massachusetts), goat anti-Ang-1 was from
Santa Cruz (Santa Cruz, CA), and horseradish peroxidase (HRP)-conjugated anti-mouse β
actin antibody was from Sigma Aldrich. Alexa 594-conjugated secondary antibody was pur-
chased from Molecular Probes (Carlsbad, CA). HRP-conjugated anti-rabbit and anti-goat
secondary antibodies were from Santa Cruz. Histochoice was purchased from Amresco
(Solon, OH).
Immunofluorescence staining
Immunofluorescence staining on paraffin sections was performed as described previously [24].
For α-SMA, collagen I, CD31 and F4/80 staining, histochoice-fixed and paraffin-embedded
sections were used. After dewaxing, the α-SMA, collagen I, CD31 antigens were retrieved by
heating the slides in citrate buffer (pH 6.0) for 10 minutes at 100°C and the F4/80 antigen was
stained without antigen retrieval. The kidney sections were blocked with 1% bovine serum
albumin (BSA) for 30 minutes at room temperature, followed by overnight incubation with the
individual primary antibody specified previously. The secondary antibody conjugated with
Alexa 594 and Hoechst 33342 to stain nuclei were used to incubate for an hour. The slides were
then mounted with anti-quench solution and visualized under a fluorescence microscope
(Leica).
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Western blot analysis
The kidneys were extracted using RIPA buffer (Sigma) with protease and phosphatase inhibitor
cocktails (Roche, Indianapolis, Indiana) and homogenized by sonication. The protein concen-
trations of kidney lysates were determined by Bio-Rad protein assay (Hercules, CA) using BSA
as a standard. Denatured proteins were separated on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes.
Blots were blocked with 5% non-fat milk for 1 hour and then incubated overnight with primary
antibodies. The membranes were washed with Tris-buffered saline/Tween buffer and incu-
bated with the appropriate HRP–conjugated secondary antibodies. The proteins were then
visualized in an x-ray developer using ECLplus detection reagents (GE, Pittsburgh, PA).
To ensure equal protein loading, the same blot was stripped with stripping buffer (25mM gly-
cine + 1% SDS, pH = 2.0) and then incubated with an anti-GAPDH or a HRP-conjugated
mouse anti-mouse β-actin antibody. Relative intensities of protein bands were quantified using
ImageJ analysis software.
mRNA quantification by Real-Time PCR
Total RNA from sham-operated or UUO kidneys was extracted using the RNeasy kit (Qiagen,
Valencia, CA) with subsequent DNase I treatment. 1 μg of kidney RNA was then reverse-tran-
scribed using an RT-PCR kit (Superscript III; Invitrogen). Gene expression was evaluated by
quantitative real-time PCR. One μl of cDNA was added to SYBR Green PCRMaster Mix (Qia-
gen) and subjected to PCR amplification (one cycle at 95°C for 20 seconds, 40 cycles at 95°C
for 1 second, and 60°C for 20 seconds) in an Applied Biosystems 7900HT Fast Real-Time PCR
System (Life Technologies, Grand Island, NY) using mouse GAPDH as an internal control.
Q-PCR was conducted in triplicate for each sample. The sequences of primers were following:
mouse α-SMA forward: CCCACCCAGAGTGGAGAA, reverse: ACATAGCTGGAGCAGCG
TCT; mouse collagen I forward: AGACATGTTCAGCTTTGTGGAC, reverse: GCAGCTGAC
TTCAGGGATG; mouse TNFα forward: ATGAGAAGTTCCCAAATGGCC, reverse: CCTCC
ACTTGGTGGTTTGCTA; mouse TGF-β1 forward: TGGAGCAACATGTGGAACTC, re-
verse: CAGCAGCCGGTTACCAAG; mouse MCP-1 forward: TTAAAAACCTGGATCGGA
ACCAA, reverse: GCATTAGCTTCAGATTTACGGGT; mouse ICAM-1 forward: AGCACCT
CCCCACCTACTTT, reverse: AGCTTGCACGACCCTTCTAA; mouse Snail1 forward: CACA
CGCTGCCTTGTGTCT, reverse: GGTCAGCAAAAGCACGGTT; mouse Twist forward:
CGGGTCATGGCTAACGTG, reverse: CAGCTTGCCATCTTGGAGTC; mouse GAPDH for-
ward: TGTAGACCATGTAGTTGAGGTCA, reverse: AGGTCGGTGTGAACGGATTTG.
Results
Generation and characterization of inducible Ang-1 transgenic mice
To investigate the effects of inducible tubular-specific Ang-1 upregulation on renal fibrosis, we
generated doxycycline (DOX) inducible Ang-1 (TETAng-1) transgenic mice and utilized a
reverse tetracycline-controlled transcriptional activator (rtTA) system (Tet-On system) (Fig
1A). In TETAng-1 transgenic mice, the mouse Ang-1 cDNA, followed by an internal ribosome
entry site (IRES) and the ZsGreen cDNA, is controlled by a (TetO)7/CMV promoter contain-
ing 7 tetracycline-response elements (TREs) (Fig 1A). The IRES permits concurrent translation
of Ang-1 and ZsGreen, the brightest known green fluorescent protein, from a single bicistronic
mRNA. Meanwhile, Pax8-rtTA (P8TA) mice direct expression of rtTA in the entire renal tubu-
lar system (Fig 1A). In the presence of the tetracycline derivative DOX, rtTA binds to TRE and
Angiopoietin-1 and Renal Fibrosis
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initiates transcription of the Ang-1 and ZsGreen cDNAs from the CMV promoter. Thus,
ZsGreen expression is indicative of concurrent Ang-1 transgene expression.
Ten TETAng-1 transgenic lines were generated, and each was bred to the P8TA line. As a
result, three genotypes were generated and abbreviated to P8TA/Ang-1, Ang-1/+ and P8TA/
+ with a similar complements of background alleles. The offspring was induced with DOX at
postnatal day 21 (P21) for 8 weeks, at which point Ang-1 expression in renal tubules was
Fig 1. Transgene constructs and experimental plan. (A) Diagram of the two constructs used in the transgenic mouse lines for the generation of
the reverse tetracycline-controlled transcriptional activator (rtTA) system (Tet-On system). a. The Pax8 promoter directs the expression of rtTA in
renal tubular cells. b. The (TetO)7/CMV-Ang-1-ZsGreen transgene is induced by a doxycycline (DOX)-bound rtTA. (B) Frozen kidney sections from
11 week-old P8TA; TETANG-1 mice receiving regular or DOX food, respectively, at three weeks of age for 8 weeks. Green fluorescent protein
(ZsGreen) was expressed in all segments of the renal tubules in double positive transgenic mice administered DOX. Scale bar, 40 μm. (C)
Representative immunoblot of Ang-1 expression in whole kidney lysates frommice of the indicated genotypes after 8 weeks of DOX
administration. (D) The experimental plan used for the UUO study. CON, control.
doi:10.1371/journal.pone.0158908.g001
Angiopoietin-1 and Renal Fibrosis
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analysed by ZsGreen expression andWestern blot (WB) with an anti-Ang-1 antibody. ZsGreen
expression was strongly induced only in cortical and medullary renal tubules of P8TA/Ang-1
kidneys in the presence of DOX, whereas its expression was not detected in P8TA/Ang-1 kid-
neys in the absence of DOX (Fig 1B) or in Ang-1/+ or P8TA/+ kidneys in the presence of DOX
(data not shown). Furthermore, as demonstrated by WB, kidney lysates from P8TA/Ang-1
mice that were treated with DOX for 8 weeks showed significantly increased Ang-1 levels com-
pared to those from mice expressing a single Ang-1 or P8TA transgene that were treated with
DOX for 8 weeks (Fig 1C) or from P8TA/Ang-1 mice in the absence of DOX (data not shown).
Consistent with a previous report [25], both glycosylated and unglycosylated forms of Ang-1
were observed in kidney tissues. For our studies, we selected the transgenic line that exhibited
the highest inducible expression of the transgene without basal leaky expression. Histologic
examination revealed no conspicuous histological changes in P8TA/Ang-1 kidneys compared
with control single-transgene kidneys that had been exposed to DOX for 8 weeks (S1 Fig).
Body weight was also not different among the above-mentioned groups (data not shown). We
therefore reasoned that this inducible transgenic strategy could be used as a means of manipu-
lating Ang-1 levels in models of renal interstitial fibrosis.
Renal tubular overexpression of Ang-1 ameliorates renal fibrosis
To evaluate the effects of renal tubular expression of Ang-1 on interstitial fibrosis, we utilized a
murine model of obstruction-induced renal injury. In this model, a UUO is created in mice by
placing a microvascular clamp on the proximal ureter [26]. UUO results in the development of
fibrotic changes in glomeruli and the interstitium that are characterized by tubular dilation and
interstitial collagen accumulation. From P21, P8TA/Ang-1, P8TA/+ or Ang-1/+ mice were fed
DOX for 8 weeks, at which point these mice underwent either sham operation or 7 days of
UUO. These mice were studied in detail when they were 12 weeks old (i.e., 9 weeks after DOX
induction) (Fig 1D). Kidney sections were stained with Picro-Sirius Red, which stains fibrils
containing type I and III collagens. As shown in Fig 2, control mice (Ang-1/+ or P8TA/+) that
were treated with DOX and subjected to UUO exhibited marked interstitial fibrosis, as indi-
cated by positive Sirius Red staining in both cortex (Fig 2A and 2B) and medulla (Fig 2C and
2D) in comparison to sham-operated, DOX-treated control mice. In contrast, renal tubular
overexpression of Ang-1 in P8TA/Ang-1 DOX mice significantly reduced the Sirius Red-posi-
tive area in both the cortex (Fig 2A and 2B) and medulla (Fig 2C and 2D) of obstructed kidneys
when compared with control mice subjected to UUO. These results convincingly demonstrate
that targeted overexpression of Ang-1 in renal tubules mitigates renal interstitial fibrosis.
Targeted tubular Ang-1 upregulation inhibits renal expression of TGF-
β1, collagen I and α-SMA
To further explore the molecular mechanisms underlying the anti-fibrotic effects of targeted
Ang-1 expression in renal tubules, we examined the renal expression of transforming growth
factor β1 (TGF-β1) in P8TA/Ang-1 DOX and control (Ang-1/+ or P8TA/+) DOX mice that
underwent either sham operation or 7 days of UUO. It is known that TGF-β1 plays a central
role in the pathogenesis of renal injury. Upon TGF-β1 stimulation, Smad2 and Smad3 are
recruited to type I TGF-β1 receptors and phosphorylated. Phosphorylated Smads then form
heteromeric complexes with the common partner Smad4 and translocate into the nucleus,
where they control the transcription of TGF-β-responsive genes [27–29]. Real-time quantita-
tive PCR (q-PCR) demonstrated that renal TGF-β1 mRNA levels were significantly upregu-
lated in obstructed control DOX kidneys following 7 days of UUO, as compared to levels in
sham-operated control DOX kidneys (Fig 3A). The upregulation of renal TGF-β1 mRNA levels
Angiopoietin-1 and Renal Fibrosis
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in UUO kidneys was attenuated by transgenic tubular Ang-1 expression in P8TA/Ang-1 DOX
kidneys (Fig 3A). Furthermore, the subsequent increase in phosphorylation of Smad 2/3 in
Fig 2. Targeted overexpression of Ang-1 in renal tubules attenuates renal interstitial fibrosis after UUO. Bitransgenic P8TA/Ang-1 or
single-transgene control mice (Ang-1/+ or P8TA/+) underwent either sham operation or 7 days of obstruction (n = 6 mice/group) after 8 weeks of
DOX administration. Fibrosis of kidney cortex (A) and medulla (C) was analyzed by Sirius Red staining under polarized light. Scale bars, 40 μm.
Morphometric quantification of Sirius Red-positive area in cortex (B) or medulla (D), respectively, from sagittal kidney sections in the indicated
groups (n = 6 mice/group). Ten photographs / kidney were uniformly taken in the cortex or medulla, respectively, at x400 magnification. Composite
microscopy images were analyzed using Image J software. * P < 0.05; ** P< 0.001 by ANOVA. CON, control.
doi:10.1371/journal.pone.0158908.g002
Angiopoietin-1 and Renal Fibrosis
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UUO control DOX kidneys, as compared to sham-operated kidneys, was attenuated by
induced tubular Ang-1 upregulation in UUO P8TA/Ang-1 DOX kidneys (Fig 3B).
It has been proposed that microvascular pericytes, perivascular fibroblasts, tubular epithelial
cells, and more recently ECs can undergo mesenchymal transition to form scar-producing
Fig 3. Targeted overexpression of Ang-1 in renal tubules downregulates TGF-β1 signaling. P8TA/Ang-1 and control (Ang-1/+ or P8TA/+) mice
underwent either sham operation or 7 days of UUO (n = 6 mice/group) after DOX treatment for 8 weeks. Kidneys were harvested for both RNA and protein
analyses at 12 weeks of age. (A) Renal TGF-β1 transcript level was assessed by quantitative RT-PCR in the indicated groups. TGF-β1 expression was
normalized as a ratio to mouse GAPDH, and the average TGF-β1/GAPDH ratio in sham-operated control mice was set as 1. Mean ± SD; ** P< 0.001 by
ANOVA. (B) Representative immunoblot analysis for phospho-Smad 2/3 and GAPDH proteins in kidney lysates from the indicated groups. (C) Quantitative
RT-PCR showed relative transcript levels of Snail1 and Twist in kidneys from the indicated groups. Absolute levels were normalized first to those of GAPDH
and then to the levels in the sham-operated control kidneys. Mean ± SD; ** P< 0.001 by ANOVA. CON, control.
doi:10.1371/journal.pone.0158908.g003
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myofibroblasts [30–33]. TGF-β signaling has been shown to induce epithelial-mesenchymal
transition (EMT) of tubular epithelial cells, thus contributing to tubulointerstitial fibrosis [34].
TGF-β induces EMT via Smad-dependent and -independent signaling pathways, and tran-
scription factors identified downstream of TGF-β signaling include Snail/Slug, Twist, ZEB1
and ZEB2 [35, 36]. As shown in Fig 3C, transcript levels of Snail1 and Twist were significantly
increased in UUO control DOX kidneys following 7 days of obstruction compared with sham-
operated kidneys. Moreover, tubular overexpression of Ang-1 in UUO P8TA/Ang-1 DOX kid-
neys mitigated the obstruction-induced increase of Snail1 and Twist mRNA levels.
Myofibroblasts are characterized by expression of α-smooth muscle actin (α-SMA) and pro-
duction of extracellular matrix (ECM) components including type I and III collagens [32, 37].
TGF-β1 can stimulate both myofibroblast activation and collagen production [38]. We thus
hypothesized that renal tubular-specific overexpression of Ang-1 can also attenuate the upre-
gulation of α-SMA and collagen I in obstructed kidneys. Indeed, q-PCR showed a significant
decrease in renal transcript levels of α-SMA and collagen I in UUO P8TA/Ang-1 DOX kidneys
when compared to UUO control DOX kidneys after 7 days of obstruction (Fig 4A and 4D).
Consistent with the q-PCR data, WB demonstrated a significant reduction of renal α-SMA
protein levels in obstructed kidneys from enhanced tubular expression of Ang-1 in P8TA/Ang-
1 DOX mice compared to control DOX mice (Fig 4B). Furthermore, immunofluorescence (IF)
staining of α-SMA (Fig 4C) and collagen I (Fig 4E) confirmed that tubular-specific overexpres-
sion of Ang-1 in UUO P8TA/Ang-1 DOX kidneys significantly inhibited upregulation of α-
SMA and collagen I in obstructed control kidneys. Collectively, these data clearly indicate that
renal tubular overexpression of Ang-1 attenuates TGF-β signaling and fibrogenesis.
Targeted tubular Ang-1 overexpression reduces UUO-induced renal
inflammation
The homing of inflammatory macrophages to renal tissues has been identified as a potent
mechanism in fibrosis progression [39, 40], and macrophage-derived factor TNFα has been
shown to be a key pathogenic regulator of UUO-induced renal fibrosis [41–43]. We next deter-
mined whether renal overexpression of Ang-1 can inhibit inflammation in obstructed kidneys.
Indeed, renal macrophage infiltration, as identified by IF staining for the F4/80 antigen, was
easily detectable in obstructed control kidneys after 7 days of injury (Fig 5A and S2 Fig). In
contrast, this increase in F4/80-positive macrophage infiltration was attenuated by tubular
Ang-1 overexpression in UUO P8TA/Ang-1 DOX kidneys (Fig 5A and S2 Fig). The subse-
quent increase in TNFα transcript levels in UUO control DOX kidneys was also reduced by
renal Ang-1 overexpression in UUO P8TA/Ang-1 DOX kidneys (Fig 5B). Consequently, trans-
genic tubular Ang-1 expression ameliorated the transcriptional induction of intercellular adhe-
sion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1), which are
target inflammatory gene and chemokine of TNFα and its downstream transcriptional factor
NFκB, in obstructed kidneys (Fig 5C). Taken together, these results demonstrate that trans-
genic Ang-1 expression in renal tubules mitigates obstruction-induced inflammation.
Effect of tubular Ang-1 overexpression on renal microvasculature
The UUO kidney injury model is characterized by an early angiogenic response and increased
capillary density persisting through day 7 and microvascular rarefaction beginning at about
day 10 after injury [44]. We further assessed the impact of site-directed Ang-1 overexpression
on the peritubular capillary compartment after obstruction-induced injury. Consistent with
previous studies, there was a significant increase in peritubular capillary density as assessed by
WB (Fig 6A and 6C) and IF staining (Fig 6D and S3 Fig) for CD31, an EC marker, on day 7
Angiopoietin-1 and Renal Fibrosis
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Fig 4. Targeted overexpression of Ang-1 in renal tubules ameliorates renal pro-fibrotic responses. DOX-treated P8TA/Ang-1 and control (Ang-1/+ or
P8TA/+) mice underwent either sham operation or 7 days of UUO (n = 6 mice/group). Kidneys were harvested for both RNA, protein and IF analyses at 12
weeks of age. (A and D) Quantitative RT-PCR showed relative transcript levels of α-SMA (A) and collagen I (D) in sham-operated or UUO kidneys from the
indicated genotypes. Absolute levels were normalized first to those of GAPDH and then to the levels in the sham-operated single transgene control kidneys.
* P < 0.05; ** P< 0.001 by ANOVA. (B) Whole kidney lysates from the indicated groups were analyzed byWB for levels of α-SMA and GAPDH.
Quantification of α-SMA was normalized to GAPDH in kidney lysates. The average α-SMA/GAPDH ratio in sham-operated control mice was set as 1.
Mean ± SD; * P < 0.05 and ** P< 0.001 by ANOVA. (C and E) IF staining with quantification for α-SMA (red) (C) or collagen I (green) (E) on paraffin kidney
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sections from the indicated groups. Original magnifications: x200. Morphometric quantification of α-SMA-(C) or collagen I-(E) positive area in cortex from
sagittal kidney sections in the indicated groups (n = 6 mice/group). Five photographs / kidney were uniformly taken in the cortex at x200 magnification.
Composite microscopy images were analyzed using Image J software. The α-SMA- or collagen I-positive area in sham-operated control mice was set as 1.
Mean ± SD; * P < 0.05; ** P< 0.001 by ANOVA. CON, control.
doi:10.1371/journal.pone.0158908.g004
Fig 5. Targeted tubular Ang-1 upregulation suppresses UUO-induced inflammation. P8TA/Ang-1 and control (Ang-1/+ or P8TA/+) mice
exposed to 8 weeks of DOX underwent either sham operation or 7 days of UUO (n = 6 mice/group). Kidneys were harvested for both IF staining
and mRNA quantification at 12 weeks of age. (A) IF staining for F4/80 (red) on paraffin kidney sections from the indicated groups. Nuclei were
counterstained with Hoechst 33342 (blue). Scale bar, 50 μm. (B) Renal TNFα transcript level was assessed by q-RT-PCR in the indicated groups.
TNFα expression was normalized as a ratio to mouse GAPDH, and the average TNFα/GAPDH ratio in sham-operated control mice was set as 1.
Mean ± SD; * P < 0.05 and ** P< 0.001 by ANOVA. (C) Quantitative RT-PCR showed relative transcript levels of ICAM-1 and MCP-1 in kidneys
from the indicated groups. Absolute levels were normalized first to those of GAPDH and then to the levels in the sham-operated control kidneys.
Mean ± SD; * P < 0.05 and ** P< 0.001 by ANOVA. CON, control.
doi:10.1371/journal.pone.0158908.g005
Angiopoietin-1 and Renal Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0158908 July 25, 2016 11 / 19
following UUO-induced injury in control kidneys compared to sham-operated kidneys. More-
over, on day 7 of UUO, there was a more robust peritubular CD31 expression in response to
enhanced tubular expression of Ang-1 in UUO P8TA/Ang-1 DOX kidneys compared to UUO
control DOX kidneys (Fig 6A, 6C and 6D). In sham-operated mice, CD31 expression was also
increased in P8TA/Ang-1 DOX kidneys compared with control DOX kidneys with much longer
exposure time (data not shown). In addition, it appears that the obstruction-induced injury
enhanced renal Ang-1 expression in UUO kidneys versus sham-operated kidneys in P8TA/Ang-
1 DOXmice (Fig 6A and 6B). Together, these data suggest that tubular Ang-1 overexpression
Fig 6. Tubular-directed Ang-1 overexpression promotes the growth of peritubular capillary network after UUO. (A) P8TA/Ang-1 and
control (Ang-1/+ or P8TA/+) mice underwent either sham operation or 7 days of UUO (n = 6 mice/group) after DOX treatment for 8 weeks. Kidneys
were harvested and lysates were analyzed byWB for levels of Ang-1, CD31, and GAPDH. Quantification of (B) Ang-1 or (C) CD31 normalized to
GAPDH in kidney lysates of the indicated groups. The average Ang-1/GAPDH or CD31/GAPDH ratio in sham-operated control mice was set as 1.
Mean ± SD; * P < 0.05 and ** P< 0.001 by ANOVA. (D) IF staining for CD31 (red) on paraffin kidney sections from DOX-treated P8TA/Ang-1 and
control (Ang-1/+ or P8TA/+) mice undergoing either sham operation or 7 days of UUO (n = 6 mice/group). Nuclei were counterstained with Hoechst
33342 (blue). Scale bar, 50 μm. CON, control.
doi:10.1371/journal.pone.0158908.g006
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induces angiogenesis and increases the renal microvasculature in conjunction with the suppres-
sion of renal fibrosis.
Discussion
Our study demonstrates for the first time that conditional overexpression of native Ang-1 in
renal tubules attenuates renal interstitial fibrosis, dampens renal inflammation, and promotes
the growth of the renal peritubular microvasculature after obstruction-induced injury. Our
findings are in accord with a previous report that Ang-1 deficiency exaggerates the fibrotic
response to injury or microvascular stress [19].
Ang-1 consists of a carboxy-terminal fibrinogen-like domain that mediates its differential
effects on Tie2 phosphorylation, a central coiled-coil domain that oligomerizes these fibrino-
gen-like domains, and a short amino (N)-terminal domain that clusters these oligomers into
multimers [45]. When Ang-1 was administered systemically by adenoviral transduction of
hepatocytes, the central coiled-coil and N-terminal superclustering domains, which are respon-
sible for the modular and multimeric structure of Ang1, led to protein aggregation and insolu-
bility in circulation. To overcome these problems, several engineered Ang-1 variants were
generated in previous studies. In COMP-Ang-1, the N-terminal portion of Ang-1 was replaced
with the short coiled-coil domains of COMP. In Ang-1, the N-terminus of Ang-1 incorpo-
rated a portion of Ang-2 together with a mutated Cys-245 in the central coiled-coil domain
[46]. These recombinant variants are different from native Ang-1 in their biological functions.
For example, COMP-Ang-1 is more potent than native Ang-1 in phosphorylating Tie2 [46]
and also induces larger vessels and increases blood flow [47], mimicking the activating muta-
tion of Tie2 found in inherited venous malformations [48]. Ang-1 with its N-terminus more
closely resembling Ang-2 could induce an inflammatory response. These different engineered
forms of Ang-1 likely account for the contradicting effects of Ang-1 observed in murine renal
fibrosis models [21, 22]. In this study, we avoided these limitations by successfully employing a
targeted transgenic strategy to demonstrate the protective effects of native Ang-1 in renal fibro-
sis in vivo.
TGF-β1/Smad signaling is the central pathway for myofibroblast activation and differentia-
tion [49, 50]. In progressive fibrogenesis, TGF-β/Smad and TNFα pathways amplify each other
to drive fibrosis and inflammation [51–53]. Here, we showed that tubular overexpression of
Ang-1 counteracts both of these UUO-induced signaling pathways. These results confirm
prior studies suggesting that the actions of Ang-1 are anti-fibrotic and anti-inflammatory. Our
data have also demonstrated that Ang-1 suppresses renal TGF-β-mediated EMT. In addition,
ECs represent a unique target for TGF-β. Recently it has been shown that partial deletion of
TGF-β receptor II in the endothelium reduces endothelial-to-mesenchymal transition
(EndoMT) and blunts renal interstitial fibrosis [54]. To further dissect the cellular mechanisms
underlying the anti-fibrotic effects of Ang-1, we will employ coculture of ZsGreen-labelled pri-
mary tubular cells overexpressing Ang-1 with primary kidney microvascular ECs in 3D colla-
gen gel to study the interaction between Ang-1/Tie2 signaling and TGF-β pathway in
endothelial cells. In addition, fibrosis and inflammation form a self-perpetuating malicious
cycle to accelerate progression of fibrosis. An important component of the inflammatory
response is the migration of leukocytes from the blood vessel into the kidney tissue. In vitro,
Ang-1 decreases permeability between endothelia by strengthening endothelial cell-cell junc-
tions [16, 55, 56]. In vivo, transgenic mice overexpressing Ang-1 in the skin reveal that skin
vessels are resistant to leakage caused by inflammatory agents [57]. It has also been shown that
Ang-1 can restore poorly remodeled and leaky vessels [58]. Finally, activation of Tie2 by Ang-1
can inhibit TNFα-induced leukocyte capillary transmigration [16] by blocking NF-κB that
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controls expression of inflammatory genes such as ICAM1 or vascular cell adhesion molecule-
1 (VCAM-1) in endothelial cells [59]. We also would like to point out that the actions of Ang-1
are not exclusively Tie-2 dependent. Ang-1 can also bind to and activate endothelial integrins
such as α5β1 to mediate its bioactivity in the absence of Tie2 [60, 61]. Future experiments will
be required to understand whether integrin complexes are stimulated by Ang-1 in renal
fibrosis.
We also found that after 7 days of UUO, CD31-positive peritubular ECs in UUO kidneys
were increased compared to sham-operated kidneys from single-transgene control mice, which
is consistent with previous reports [21, 44]. Moreover, the increase in peritubular capillary den-
sity was accentuated by tubular overexpression of Ang-1, suggesting that Ang-1 can stimulate
angiogenesis and growth of peritubular capillaries following UUO. This effect might be due to
Ang-1 directly enhancing proliferation [47] or preventing endothelial apoptosis [62], which
warrants further investigation. Moreover, we plan to use a recently reported fluorescence
microangiography technique [63] to visualize and quantify the difference in peritubular capil-
lary perfusion between control and Ang-1 overexpressing mice.
The molecular mechanisms controlling developmental and pathogenic angiogenesis are
complex and involve a coordinated effort among endothelial growth factors and their recep-
tors. VEGF and angiopoietin are two major endothelial signaling pathways modulating angio-
genesis. Both upregulation and downregulation of VEGF in podocytes [64, 65] or renal tubules
[66, 67] at any time point have profound effects on the glomerular filtration barrier or tubu-
lointerstitial compartments, respectively. For instance, postnatal overexpression of VEGF in
renal tubules of Pax8-rtTA/(tetO)7VEGF mice causes capillary-rich interstitial fibrosis, cyst
formation and disruption of glomerular architecture [67]. On the other hand, embryonic or
postnatal ablation of tubular VEGF results in the formation of a smaller kidney with a striking
reduction in the peritubular capillary density and polycythemia due to increased renal erythro-
poietin production [66]. In contrast, although the Ang-1/Tie2 pathway is critical for vessel
development, as conventional Ang-1 or Tie2 knockout mice exhibit lethality between E9.5 and
E12.5 with similar abnormal vascular phenotypes [9, 68], global deletion of Ang-1 from E13.5
onward does not impair vascular integrity or increase permeability in mature, quiescent vascu-
lar beds [19]. Our results showed that expression of excess Ang-1 in renal tubules starting at
three weeks of age does not result in overt tubular or capillary structural abnormality. These
data strongly suggest that the Ang-1/Tie2 signaling pathway is an appealing therapeutic target
to protect against renal tubulointerstitial fibrosis since manipulation may selectively control
microvascular injury without compromising the normal vascular function.
Supporting Information
S1 Fig. No obvious histological abnormality was observed in P8TA/Ang-1 kidneys com-
pared with control kidneys after 8 weeks of DOX administration. The Ang-1 overexpression
in P8TA/Ang-1 kidneys was induced by DOX at 3 weeks of age. Scale bar, 40 μm.
(PDF)
S2 Fig. Paraffin kidney sections from mice of the indicated groups were examined by
immunofluorescence staining for F4/80 (red). Nuclei were counterstained with Hoechst
33342 (blue). Individual and merged images were shown as indicated. Scale bar, 250 μm. CON,
control.
(PDF)
S3 Fig. Paraffin kidney sections from the indicated groups were stained for CD31 (red).
Nuclei were counterstained with Hoechst 33342 (blue). Individual and merged images were
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shown as indicated. Scale bar, 250 μm. CON, control.
(PDF)
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